Kiromic Biopharma Inc.

Kiromic Biopharma Inc. is a clinical-stage biotherapeutics company focused on the development of innovative cell-based therapies for cancer treatment. As a fully integrated enterprise, Kiromic specializes in harnessing the potential of allogeneic Gamma Delta T-cell (GDT) technologies to target a range of solid tumors. The company’s approach leverages its proprietary DIAMOND artificial intelligence platform, designed to accelerate the discovery of novel immuno-oncology targets and streamline drug development processes. Kiromic’s therapeutic portfolio includes key candidates such as Deltacel-01, an allogeneic off-the-shelf GDT cell therapy in Phase 1 clinical trials for non-small cell lung cancer, along with other products like Procel and Isocel, which target PD-L1 and Mesothelin Isoform 2 positive tumors, respectively. These candidates utilize both engineered and non-engineered GDT cells, reflecting the company’s commitment to next-generation cell therapies. Operating within the biotechnology and medical research domain, Kiromic Biopharma plays a role in advancing immunotherapies aimed at improving outcomes for patients with difficult-to-treat cancers.